CD47 and neoplasm: The rationale for the sequential treatment and fewer doses in approach 3 was to ensure that SRF231 could target/bind a ‘live’ CD47 clustering on a non-compromised cell surface to drive its anti-tumor effect, as venetoclax treatment could potentially disrupt cell surface integrity due to membrane degradation from late apoptosis.